It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMFPF’s FA Score shows that 0 FA rating(s) are green whileNSVGF’s FA Score has 0 green FA rating(s).
AMFPF (@Medical Distributors) experienced а -9.41% price change this week, while NSVGF (@Medical Distributors) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +2.67%. For the same industry, the average monthly price growth was -1.02%, and the average quarterly price growth was -12.39%.
Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
AMFPF | NSVGF | AMFPF / NSVGF | |
Capitalization | 8.23B | 4.72M | 174,386% |
EBITDA | 520M | -1.57M | -33,178% |
Gain YTD | -10.394 | -87.500 | 12% |
P/E Ratio | 40.21 | N/A | - |
Revenue | 2.22B | 29.5K | 7,538,983% |
Total Cash | 198M | 0 | - |
Total Debt | 1.58B | 1.24M | 127,508% |
AMFPF | ||
---|---|---|
OUTLOOK RATING 1..100 | 97 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 40 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 58 | |
PRICE GROWTH RATING 1..100 | 82 | |
P/E GROWTH RATING 1..100 | 57 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RSI ODDS (%) |
Stochastic ODDS (%) |
Momentum ODDS (%) |
MACD ODDS (%) |
TrendWeek ODDS (%) |
TrendMonth ODDS (%) |
Advances ODDS (%) |
Declines ODDS (%) |
BollingerBands ODDS (%) |
Aroon ODDS (%) |
A.I.dvisor tells us that AMFPF and ZYXI have been poorly correlated (+10% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AMFPF and ZYXI's prices will move in lockstep.
Ticker / NAME | Correlation To AMFPF | 1D Price Change % | ||
---|---|---|---|---|
AMFPF | 100% | N/A | ||
ZYXI - AMFPF | 10% Poorly correlated | +3.18% | ||
COSM - AMFPF | 2% Poorly correlated | +5.56% | ||
NSVGF - AMFPF | 1% Poorly correlated | N/A | ||
SHPMY - AMFPF | 0% Poorly correlated | N/A | ||
MAHLY - AMFPF | 0% Poorly correlated | N/A | ||
More |
A.I.dvisor tells us that NSVGF and SHPMY have been poorly correlated (+14% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NSVGF and SHPMY's prices will move in lockstep.
Ticker / NAME | Correlation To NSVGF | 1D Price Change % | ||
---|---|---|---|---|
NSVGF | 100% | N/A | ||
SHPMY - NSVGF | 14% Poorly correlated | N/A | ||
ZYXI - NSVGF | 8% Poorly correlated | +3.18% | ||
PDRX - NSVGF | 8% Poorly correlated | N/A | ||
SHTDF - NSVGF | 4% Poorly correlated | N/A | ||
AMFPF - NSVGF | 1% Poorly correlated | N/A | ||
More |